A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy (TdVax)

Duke University logo

Duke University

Status and phase

Enrolling
Phase 1

Conditions

Melanoma

Treatments

Biological: Polio Boost Immunization
Biological: Tetanus Diptheria Vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT05077137
Pro00108367

Details and patient eligibility

About

The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the vaccine at cycle 4 of IO therapy and will have research blood and tissue samples collected prior to starting IO therapy, at cycle 4 prior to vaccine administration, and at 12-17 days post vaccine.

Enrollment

25 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed advanced metastatic melanoma
  • Male or female participants who are at least 18 years of age on the day of signing informed consent
  • Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti CTLA-4 therapy as standard of care
  • Participant (or legally acceptable representative if applicable) provides written informed consent for the trial
  • Participant must have at least 1 lesion that is at least 8 mm in size and is cutaneous, subcutaneous, palpable, or amenable to ultrasound guided core biopsy. The lesion chosen for biopsy can also be a target lesion but does not have to be a target lesion

Adequate organ function as defined below. Standard of care labs drawn within 45 days prior to consent may be used for the purposes of determining eligibility

  • ANC >/= 1500/uL
  • platelets >/=100,000/uL
  • Hemoglobin >/= 9.0 g/dL

Exclusion criteria

  • Uveal or mucosal melanoma
  • Any women known to be pregnant or breastfeeding
  • Any prior systemic therapy for metastatic melanoma (prior surgery is allowed)
  • Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy

Patients with symptomatic CNS metastases and/or carcinomatous meningitis

a) Patients with asymptomatic, stable CNS metastases are allowed provided that they are not on >10mg prednisone daily

  • History of or active (non-infectious) pneumonitis that required steroids
  • Active infection requiring systemic therapy
  • Known history of Human Immunodeficiency Virus (HIV) infection
  • Known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. NOTE: no testing for Hepatitis B or Hepatitis C is required
  • Known history of active TB (Bacillus Tuberculosis)
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • History of allogenic tissue or solid organ transplant
  • History of allergic reaction to IPOL or Td vaccine
  • Receipt of Td vaccine within 30 days prior to starting IO therapy

Trial design

25 participants in 2 patient groups

Td Vaccine
Experimental group
Description:
The first 15 subjects enrolled will receive the Td (tetanus diphtheria) vaccine at cycle 4 of IO therapy. The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.
Treatment:
Biological: Tetanus Diptheria Vaccine
IPOL Vaccine
Experimental group
Description:
Subjects 16 through 25 will receive the IPOL (polio booster) vaccine at cycle 4 of IO therapy. The IPOL vaccine is administered as 0.5 mL intramuscular or subcutaneous injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor
Treatment:
Biological: Polio Boost Immunization

Trial contacts and locations

0

Loading...

Central trial contact

Carol Ann Wiggs, BSN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems